{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:31Z","timestamp":1789794151671,"version":"4.0.1"},"reference-count":38,"publisher":"Japan Atherosclerosis Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5551\/jat.66345","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:10:52Z","timestamp":1789683052000},"source":"Crossref","is-referenced-by-count":0,"title":["Harmonization of Lipoprotein(a) Immunoassays with the IFCC- Endorsed Reference Measurement Procedure Validated in Patient Samples and Multiple Routine testing as A Second Step Towards Apolipoprotein Standardization"],"prefix":"10.5551","author":[{"given":"Keita","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine"},{"name":"Molecular and Genetic Epidemiology Laboratory, University of Tsukuba Institute of Medicine"},{"name":"Tsukuba Medical Laboratory of Education and Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Wakita","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Juntendo University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Niizeki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Juntendo University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Tokyo Women\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Tokyo Women\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Chiba University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Chiba University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Kimura","sequence":"additional","affiliation":[{"name":"Institute for Education and Student Support, Gunma University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Gunma University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Gunma University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert W","family":"Vesper","sequence":"additional","affiliation":[{"name":"Protein Biomarker and Lipid Reference Laboratory, Clinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa M","family":"Cobbaert","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miida","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science, Juntendo University Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the JSLM, JSCC, JCCLS and JACRI joint Working Group on Japan research project on the global standardization\/harmonization of Lipoprotein (a) measurement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, Ohira T, Nakamura M, Yamagishi K, Ikeda A, Shimamoto T and Iso H: Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Prev Med, 2011; 52: 381-386","DOI":"10.1016\/j.ypmed.2011.02.019"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y and Okayama A: Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study. Atherosclerosis, 2009; 203: 587-592","DOI":"10.1016\/j.atherosclerosis.2008.07.020"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Imran TF, Khan AA, Has P, Jacobson A, Bogin S, Khalid M, Khan A, Kim S, Erqou S, Choudhary G, Aspry K and Wu WC: Proprotein convertase subtilisn\/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PLoS One, 2023; 18: e0295359","DOI":"10.1371\/journal.pone.0295359"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Takahashi D, Wada H, Ogita M, Yasuda K, Nishio R, Takeuchi M, Shitara J, Tsuboi S, Dohi T, Suwa S, Miyauchi K, Daida H and Minamino T: Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. Am J Cardiol, 2022; 168: 11-16","DOI":"10.1016\/j.amjcard.2021.12.014"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Konishi H, Miyauchi K, Kasai T, Tsuboi S, Ogita M, Naito R, Sai E, Fukushima Y, Katoh Y, Okai I, Tamura H, Okazaki S and Daida H: Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol, 2015; 115: 157-160","DOI":"10.1016\/j.amjcard.2014.10.015"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS and Catapano AL: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J, 2022; 43: 3925-3946","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Lamina C: Mendelian Randomization: Principles and its usage in Lp(a) research. Atherosclerosis, 2022; 349: 36-41","DOI":"10.1016\/j.atherosclerosis.2022.04.013"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Berg K: A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. Acta Pathol Microbiol Scand, 1963; 59: 369-382","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Schmidt K, Noureen A, Kronenberg F and Utermann G: Structure, function, and genetics of lipoprotein (a). J Lipid Res, 2016; 57: 1339-1359","DOI":"10.1194\/jlr.R067314"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Par\u00e9 G, \u00c7aku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X and Yusuf S: Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 2019; 139: 1472-1482","DOI":"10.1161\/CIRCULATIONAHA.118.034311"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kronenberg F: Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis, 2022; 349: 123-135","DOI":"10.1016\/j.atherosclerosis.2022.04.008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cegla J, France M, Marcovina SM and Neely RDG: Lp(a): When and how to measure it. Ann Clin Biochem, 2021; 58: 16-21","DOI":"10.1177\/0004563220968473"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Miida T, Hirayama S, Fukushima Y, Hori A, Ito S, Hinata M, Wakita M, Tabata H, Tamura Y, Watada H, Kawamori R, Vesper HW and Cobbaert CM: Harmonization of Lipoprotein(a) Immunoassays Using A Serum Panel Value Assigned with The IFCC-Endorsed Mass Spectrometry-Based Reference Measurement Procedure as A First Step Towards Apolipoprotein Standardization. J Atheroscler Thromb, 2025; 32: 580-595","DOI":"10.5551\/jat.65238"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ruhaak LR, Romijn F, Begcevic Brkovic I, Kuklenyik Z, Dittrich J, Ceglarek U, Hoofnagle AN, Althaus H, Angles-Cano E, Coassin S, Delatour V, Deprez L, Dikaios I, Kostner GM, Kronenberg F, Lyle A, Prinzing U, Vesper HW and Cobbaert CM: Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests. Clin Chem, 2023; 69: 251-261","DOI":"10.1093\/clinchem\/hvac204"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Danilenko U, Vesper HW, Myers GL, Clapshaw PA, Camara JE and Miller WG: An updated protocol based on CLSI document C37 for preparation of off-the-clot serum from individual units for use alone or to prepare commutable pooled serum reference materials. Clin Chem Lab Med, 2020; 58: 368-374","DOI":"10.1515\/cclm-2019-0732"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama, 2013; 310: 2191-2194","DOI":"10.1001\/jama.2013.281053"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Dati F, Tate JR, Marcovina SM and Steinmetz A: First WHO\/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay -- Lp(a) SRM 2B. Clin Chem Lab Med, 2004; 42: 670-676","DOI":"10.1515\/CCLM.2004.114"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rohlfing CL, Parvin CA, Sacks DB and Little RR: Comparing analytic performance criteria: evaluation of HbA1c certification criteria as an example. Clin Chim Acta, 2014; 433: 259-263","DOI":"10.1016\/j.cca.2014.03.034"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Aarsand AK, R\u00f8raas T, Fernandez-Calle P, Ricos C, D\u00edaz-Garz\u00f3n J, Jonker N, Perich C, Gonz\u00e1lez-Lao E, Carobene A, Minchinela J, Co\u015fkun A, Sim\u00f3n M, \u00c1lvarez V, Bartlett WA, Fern\u00e1ndez-Fern\u00e1ndez P, Boned B, Braga F, Corte Z, Aslan B and Sandberg S: The Biological Variation Data Critical Appraisal Checklist: A Standard for Evaluating Studies on Biological Variation. Clin Chem, 2018; 64: 501-514","DOI":"10.1373\/clinchem.2017.281808"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Arsenault BJ and Kamstrup PR: Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime. Eur Heart J, 2024; 45: 2692-2694","DOI":"10.1093\/eurheartj\/ehae191"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kronenberg F, Bedlington N, Ademi Z, Geant\u0103 M, Silberzahn T, Rijken M, Kaal A, Harada-Shiba M, Chen Z, Thanassoulis G, Eliasen B, Eisel\u00e9 J-L, Wiegman A, Ballantyne CM, Broome E, Calabr\u00f2 M, Corral P, Dol A, Donato LJ, Evans E, Funabashi S, Gouni-Berthold I, Ibarluzea IG, Johnson N, Lane J, Mora S, Nordestgaard BG, Pe\u0107in I, Kaal-Poppelaars R, Langlois MR, Ray KK, Rodenbach A, Santos RD, Stroes ESG, Tada H, Vrabl\u00edk M, Winokur M, Yoshida M, Nicholls SJ and Daccord M: The Brussels International Declaration on Lipoprotein(a) Testing and Management. Atherosclerosis, 2025; 406: 119218","DOI":"10.1016\/j.atherosclerosis.2025.119218"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, Chen ZY, Guo YL, Wu NQ, Yan SK, Wang ZW and Gao RL: 2023 Chinese guideline for lipid management. Front Pharmacol, 2023; 14: 1190934","DOI":"10.3389\/fphar.2023.1190934"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L and Wiklund O: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Boffa MB: Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. Curr Atheroscler Rep, 2016; 18: 69","DOI":"10.1007\/s11883-016-0622-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tsimikas S, Gordts P, Nora C, Yeang C and Witztum JL: Statin therapy increases lipoprotein(a) levels. Eur Heart J, 2020; 41: 2275-2284","DOI":"10.1093\/eurheartj\/ehz310"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C and Campion GV: Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. Jama, 2022; 327: 1679-1687","DOI":"10.1001\/jama.2022.5050"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Malick WA, Goonewardena SN, Koenig W and Rosenson RS: Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2\/3. J Am Coll Cardiol, 2023; 81: 1633-1645","DOI":"10.1016\/j.jacc.2023.02.033"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Marcovina SM, Albers JJ, Gabel B, Koschinsky ML and Gaur VP: Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem, 1995; 41: 246-255","DOI":"10.1093\/clinchem\/41.2.246"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ruhaak LR and Cobbaert CM: Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. Clin Chim Acta, 2020; 511: 260-268","DOI":"10.1016\/j.cca.2020.10.010"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Furbee JW, Jr. and Fless GM: Evaluation of common electrophoretic methods in determining the molecular weight of apolipoprotein(a) polymorphs. Anal Biochem, 1996; 234: 66-73","DOI":"10.1006\/abio.1996.0051"},{"key":"#cr-split#-32.1","doi-asserted-by":"crossref","unstructured":"32) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS and Catapano AL: Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis, 2023","DOI":"10.1016\/j.atherosclerosis.2023.04.012"},{"key":"#cr-split#-32.2","unstructured":"32) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS and Catapano AL: Frequent questions and responses on the 2022 lipoprotein"},{"key":"#cr-split#-32.3","doi-asserted-by":"crossref","unstructured":"(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis, 2023; 374: 107-120","DOI":"10.1016\/j.atherosclerosis.2023.04.012"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S and Khera AV: Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol, 2021; 41: 465-474","DOI":"10.1161\/ATVBAHA.120.315291"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Fujii E, Ako J, Takahashi Y, Toda M, Iekushi K and Yamashita S: Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan. J Atheroscler Thromb, 2025; 32: 421-438","DOI":"10.5551\/jat.64953"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Cobbaert CM, Althaus H, Begcevic Brkovic I, Ceglarek U, Coassin S, Delatour V, Deprez L, Dikaios I, Dittrich J, Hoofnagle AN, Kostner GM, Kronenberg F, Kuklenyik Z, Prinzing U, Vesper HW, Zegers I and Ruhaak LR: Towards an SI-Traceable Reference Measurement System for Seven Serum Apolipoproteins Using Bottom-Up Quantitative Proteomics: Conceptual Approach Enabled by Cross-Disciplinary\/Cross-Sector Collaboration. Clin Chem, 2021; 67: 478-489","DOI":"10.1093\/clinchem\/hvaa239"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL and Marcovina SM: Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. J Clin Lipidol, 2018; 12: 1313-1323","DOI":"10.1016\/j.jacl.2018.07.003"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_66345\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:32:47Z","timestamp":1789792367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_66345\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":38,"URL":"https:\/\/doi.org\/10.5551\/jat.66345","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"66345"}}